ABSTRACT
We aimed to identify plasma cell-free transcripts (cfRNA) associated with Parkinson’s disease (PD) that also have a high predictive value to differentiate PD from healthy controls. Leveraging two independent populations from two different movement disorder centers we identified 2,188 differentially expressed cfRNAs after meta-analysis. The identified transcripts were enriched in PD relevant pathways, such as PD (p=9.26×10-4), ubiquitin-mediated proteolysis (p=7.41×10-5) and endocytosis (p=4.21×10-6). Utilizing in-house and publicly available brain, whole blood, and acellular plasma transcriptomic and proteomic PD datasets, we found significant overlap across dysregulated biological species in the different tissues and the different biological layers. We developed three predictive models containing increasing number of transcripts that can distinguish PD from healthy control with an area under the ROC Curve (AUC) ≥0.85. Finally, we showed that several of the predictive transcripts significantly correlate with symptom severity measured by UPDRS-III. Overall, we have demonstrated that cfRNA contains pathological signatures and has the potential to be utilized as biomarker to aid in PD diagnostics and monitoring.
Competing Interest Statement
The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. SY is an employee of Daiichi Sankyo Co., Ltd. LI and AB are named as inventors on the invention disclosure filed in relation to this work. The rest of the authors report no conflict of interest.
Funding Statement
This work was supported by grants from the National Institutes of Health K99/R00-AG062723, P01AG003991, RO1 NS075321, P30 AG066444, P01 AG03991, and P01 AG026276, the Michael J Fox Foundation (MJFF-021599 and MJFF-025292), the Alzheimer's Drug Discovery Foundation (GDAPB-201807-2015632), Bright Focus Foundation (A2021033S), and the Department of Defense (W81XWH2010849).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Washington University in Saint Louis Institutional Review Board approved the study (IRB ID 201701124 and 202004010).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY
Data is available from the NIAGADS Data Sharing Service (NIAGADS dss), accession number NG00142. All original code has been deposited at GitHub (https://github.com/Ibanez-Lab/PlasmaCellFreeRNA-ParkinsonDisease) and is publicly available as of the date of publication. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
